<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1004257222
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAXIRA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROCURONIUM BROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        182.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LAXIRA is one of a group of drugs called muscle relaxants.</p><p>Muscle relaxants are used during an operation as part of the general anesthetic. When you have an operation, your muscles must be completely relaxed. This makes it easier for the surgeon to perform the operation.</p><p>Normally the nerves send messages called impulses to your muscles. LAXIRA acts by blocking these impulses so that the muscles relax. Because the breathing muscles also relax, you will need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again.</p><p>During the operation your anesthetist will keep a check on the effect of the muscle relaxant and if necessary, will give you some more. At the end of surgery, the effects of the drug are allowed to wear off and you can start breathing on your own. Sometimes the anesthetist will give you another drug to help speed this up.</p><p>LAXIRA can also be used in Intensive Care Units for short term use to keep your muscles relaxed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not receive LAXIRA </strong></p><p>- if you are allergic (hypersensitive) to rocuronium, the bromide ion or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Tell your anesthetist if this applies to you. </strong></p><p><strong>Warnings and precautions </strong></p><p>Talk to your anesthetist before you receive this medicine:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to <strong>muscle relaxants </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had <strong>kidney, heart, liver </strong>or <strong>gall bladder </strong>disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had diseases affecting the <strong>nerves </strong>and <strong>muscles </strong>(e.g.poliomyelitis, myasthenia gravis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>fluid retention </strong>(oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of malignant hyperthermia (sudden fever with rapid heartbeat, rapid breathing and stiffness, pain and/or weakness in your muscles)</p><p>&nbsp;</p><p><strong>Some conditions may influence the effects of LAXIRA&mdash; for example: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low calcium levels in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low potassium levels in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high magnesium levels in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of protein in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too much carbon dioxide in the blood (acidosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of too much water from the body, for example by being sick, diarrhoea or sweating (dehydration)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; over-breathing leading to too little carbon dioxide in the blood (alkalosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general ill-health</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being very overweight (obesity)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burns</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very low body temperature (hypothermia)</p><p>If you have any of these conditions, your anesthetist will take it into account when deciding the correct dose of LAXIRA for you.</p><p><strong>Children and elderly </strong></p><p>LAXIRA can be used in children (newborns and adolescents) and elderly but your anesthetist should first assess your medical history.</p><p><strong>Other medicines and LAXIRA </strong></p><p><strong>Tell your anesthetist if you are taking </strong>or have recently taken any other medicines. LAXIRA may affect other medicines or be affected by them.</p><p><strong>Medicines which increase the effect of LAXIRA: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain <strong>antibiotics </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines for <strong>heart diseases </strong>or <strong>high blood pressure </strong>(water tablets, calcium channel blockers, beta-blockers and quinidine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain <strong>anti-inflammatory </strong>medicines (corticosteroids)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; magnesium salts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines used for <strong>bipolar disorder </strong>(lithium salts)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines used to treat <strong>malaria </strong>(quinine).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines <strong>used to make you sleep </strong>during surgery (anesthetics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines which cause <strong>increased volume of urine </strong>(diuretics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain <strong>local anesthetics </strong>(lidocaine, bupivacaine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines for <strong>epilepsy </strong>during an operation (phenytoin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines used to <strong>induce short-term muscle relaxation </strong>in anesthesia and intensive care (suxamethonium)</p><p>&nbsp;</p><p><strong>Medicines which decrease the effect of LAXIRA: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long term use of medicines for <strong>epilepsy </strong>(phenytoin and carbamazepine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain <strong>protease inhibitors </strong>called gabexate and ulinastatin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetylcholinesterase inhibitors, medicines for the <strong>treatment of myasthenia gravis </strong>(e.g. neostigmine, edrophonium, pyridostigmine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>calcium chloride </strong>and <strong>potassium chloride </strong></p><p>&nbsp;</p><p>In addition, you may be given other medicines before or during surgery which can alter the effects of rocuronium. These include certain anaesthetics, other muscle relaxants, medicines such as phenytoin and medicines which reverse the effects of LAXIRA. Rocuronium may make certain anaesthetics work more quickly. Your anaesthetist will take this into account when deciding the correct dose of LAXIRA for you.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your anaesthetist for advice before receiving this medicine.</p><p>Your anaesthetist may still give you LAXIRA but you need to discuss it first. LAXIRA may be given to you if you are having a Caesarean section.</p><p>Breastfeeding should be suspended 6 hours after use of this medicine.</p><p><strong>Driving and using machines </strong></p><p>Do not drive or use machines until advised it is safe to do so. Because LAXIRA is given as part of a general anaesthetic, you may feel tired, weak or dizzy for some time afterwards. Your anaesthetist will be able to advise you on how long the effects are likely to last.</p><p><strong>LAXIRA contains sodium </strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per /ampoule, that is to say essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dose </strong></p><p>Your anesthetist will work out the dose of LAXIRA you need based on:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the type of anesthetic</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the expected length of the operation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other drugs you are taking</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your state of health</p><p>The normal dose is 0.6 mg per kg body weight and the effect will last 30 - 40 minutes.</p><p><strong>How LAXIRA is given </strong></p><p>LAXIRA will be given to you by your anesthetist. LAXIRA is given intravenously (into a vein), either as single injections or as a continuous infusion (a drip).</p><p>This medicine is for single use only. Any unused solution for injection/infusion should be discarded.</p><p><strong>If more LAXIRA is given to you than recommended </strong></p><p>As your anesthetist will be monitoring your condition carefully it is unlikely that you will be given too much LAXIRA. However, if it happens, your anesthetist will keep you breathing artificially (on a ventilator) until you breathe on your own. You will be kept asleep while this takes place.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If these side effects occur while you are under anesthetic, they will be seen and treated by your anesthetist.</p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in heart rate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lowering of blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The drug is too effective or not effective enough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The drug works for longer than expected</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain near the site of injection</p><p>&nbsp;</p><p><strong>Very rare (may affect up to 1 in 10,000 people ) </strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reactions (such as difficulty in breathing, collapse of the circulation and shock)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wheezing of the chest</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling, a rash or wheals or redness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long term muscle dysfunction usually observed when LAXIRA and anti-inflammatory medicines (corticosteroids are used in the Intensive Care Unit at the same time in critically ill patients (steroid myopathy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Airway complication of anesthesia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic coronary blood vessels spasm (Kounis syndrome) resulting in chest pain (angina) or heart attack (myocardial infarction)</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><p><strong>If any of these side effects get serious, </strong>or if you notice any side effects not listed in this leaflet, <strong>Tell your anesthetist or other doctor. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the ampoule label and carton after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2&deg;C-8&deg;C).</p><p>Do not freeze.</p><p>Keep the ampoule in the outer carton in order to protect from light.</p><p>LAXIRA may also be stored outside the refrigerator at a temperature of up to 25&deg;C for a maximum of 12 weeks.</p><p>The solution should be used immediately after opening the ampoule.</p><p>In-use shelf life of diluted medicinal product</p><p>After dilution with infusion fluids, chemical and physical in-use stability has been demonstrated for 24 hours at 25&deg;C. From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user/administrator and would normally not be longer than 24 hours at 2 to 8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>Do not use this medicine if you notice that the solution is not clear and not free from particles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: rocuronium bromide.</p><p>Each ml of solution for injection/infusion contains 10 mg rocuronium bromide.</p><p>Each ampoule with 5 ml contains 50 mg rocuronium bromide.</p><p>The other ingredients are:</p><p>Sodium Chloride, Sodium Acetate Anhydrous, Glacial Acetic Acid 30%, Sodium Hydroxide BP, Nitrogen, Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rocuronium 10 mg/ml solution for injection/infusion is a clear, colorless up to pale brown-yellowish solution, free visible particles
Ampoules of 5 ml 
Pack sizes: 
10 x 5 ml Ampoules
Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لاكسيرا هو واحد من مجموعة من الأدوية تسمى مرخيات العضلات.</p><p dir="RTL">تستخدم مرخيات العضلات أثناء العملية كجزء من التخدير العام. عندما تجري عملية جراحية، يجب أن تكون عضلاتك مسترخية تماما. هذا يجعل من السهل على الجراح إجراء العملية.</p><p dir="RTL">عادة ما ترسل الأعصاب رسائل تسمى النبضات إلى عضلاتك. يعمل لاكسيرا عن طريق منع هذه النبضات بحيث تسترخي العضلات. نظرا لأن عضلات التنفس تسترخي أيضا، فستحتاج إلى مساعدة للتنفس (التهوية الاصطناعية) أثناء العملية وبعدها حتى تتمكن من التنفس بمفردك مرة أخرى.</p><p dir="RTL">أثناء العملية، سيراقب طبيب التخدير الخاص بك تأثير مرخيات العضلات وإذا لزم الأمر، سيعطيك المزيد. في نهاية الجراحة، يسمح لآثار الدواء بالتلاشي ويمكنك البدء في التنفس بنفسك. في بعض الأحيان، سيعطيك طبيب التخدير دواء آخر للمساعدة في تسريع ذلك.</p><p dir="RTL">يمكن أيضا استخدام لاكسيرا في وحدات العناية المركزة للاستخدام على المدى القصير للحفاظ على استرخاء عضلاتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا تتلقى لاكسيرا </strong></p><p dir="RTL">- إذا كنت تعاني من حساسية (الحساسية الشديدة) من الروكورونيوم أو أيون البروميد أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL"><strong>أخبر طبيب التخدير الخاص بك إذا كان هذا ينطبق عليك. </strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات </strong></p><p dir="RTL">تحدث إلى طبيب التخدير قبل تلقي هذا الدواء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من <strong>مرخيات العضلات </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بأمراض الكلى<strong> أو القلب أو الكبد </strong>أو <strong>المرارة </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض تؤثر على <strong>الأعصاب </strong>والعضلات <strong>(</strong>مثل شلل الأطفال والوهن العضلي الوبيل)&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>احتباس السوائل </strong>(الوذمة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من ارتفاع الحرارة الخبيث (حمى مفاجئة مع سرعة ضربات القلب والتنفس السريع والتصلب والألم و / أو الضعف في عضلاتك)</p><p>&nbsp;</p><p dir="RTL"><strong>قد تؤثر بعض الحالات على آثار لاكسيرا &mdash; على سبيل المثال: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الكالسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات المغنيسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البروتين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكثير من ثاني أكسيد الكربون في الدم (الحماض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الكثير من الماء من الجسم، على سبيل المثال بسبب المرض أو الإسهال أو التعرق (الجفاف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في التنفس مما يؤدي إلى تركيز قليل جدا من ثاني أكسيد الكربون في الدم (قلواس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الصحة العام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن جدا (السمنة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درجة حرارة الجسم منخفضة جدا (انخفاض حرارة الجسم)</p><p dir="RTL">إذا كان لديك أي من هذه الحالات، فسوف يأخذها طبيب التخدير في الاعتبار عند تحديد الجرعة الصحيحة من لاكسيرا لك.</p><p dir="RTL"><strong>الأطفال وكبار السن </strong></p><p dir="RTL">يمكن استخدام لاكسيرا في الأطفال (حديثي الولادة والمراهقين) وكبار السن ولكن يجب على طبيب التخدير أولا تقييم تاريخك الطبي.</p><p dir="RTL"><strong>أدوية أخرى ولاكسيرا </strong></p><p dir="RTL"><strong>أخبر طبيب التخدير الخاص بك إذا كنت تتناول </strong>أو تناولت مؤخرا أي أدوية أخرى. قد يؤثر لاكسيرا على أدوية أخرى أو يتأثر بها.</p><p dir="RTL"><strong>الأدوية التي تزيد من تأثير لاكسيرا: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض <strong>المضادات الحيوية </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية <strong>لأمراض القلب </strong>أو <strong>ارتفاع ضغط الدم </strong>(أقراص الماء، حاصرات قنوات الكالسيوم، حاصرات بيتا والكينيدين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية <strong>المضادة للالتهابات </strong>(الكورتيكوستيرويدات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح المغنيسيوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة <strong>للاضطراب الثنائي القطب </strong>(أملاح الليثيوم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة لعلاج <strong>الملاريا </strong>(الكينين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية <strong>المستخدمة لتجعلك تنام </strong>أثناء الجراحة (التخدير)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تسبب <strong>زيادة حجم البول </strong>(مدرات البول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية <strong>التخدير الموضعي</strong> (ليدوكايين، بوبيفاكايين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية <strong>الصرع </strong>أثناء العملية (الفينيتوين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة <strong>للحث على استرخاء العضلات على المدى القصير </strong>في التخدير والعناية المركزة (سوكساميثونيم)</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية التي تقلل من تأثير لاكسيرا: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستخدام طويل الأجل لأدوية <strong>الصرع </strong>(الفينيتوين والكاربامازيبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض <strong>مثبطات الأنزيم البروتيني </strong>تسمى جابيكسات وأوليناستاتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الأسيتيل كولينستراز، أدوية <strong>لعلاج الوهن العضلي الوبيل </strong>(مثل النيوستيغمين، الإدروفونيوم، البيريدوستيغمين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كلوريد الكالسيوم </strong>وكلوريد<strong> البوتاسيوم </strong></p><p>&nbsp;</p><p dir="RTL">بالإضافة إلى ذلك، قد يتم إعطاؤك أدوية أخرى قبل أو أثناء الجراحة والتي يمكن أن تغير آثار الروكورونيوم. وتشمل هذه بعض أدوية التخدير، ومرخيات العضلات الأخرى، والأدوية مثل الفينيتوين والأدوية التي تعكس آثار لاكسيرا. قد يجعل الروكورونيوم بعض أدوية التخدير يعمل بسرعة أكبر. سيأخذ طبيب التخدير هذا في الاعتبار عند تحديد الجرعة الصحيحة من لاكسيرا لك.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إذا كنت حاملا أو مرضعة، أو تعتقدين أنك قد تكونين حاملا أو تخططين لإنجاب طفل، فاطلبي من طبيب التخدير المشورة قبل تلقي هذا الدواء.</p><p dir="RTL">قد يستمر طبيب التخدير الخاص بك بإعطائك لاكسيرا ولكنك تحتاجين إلى مناقشته أولا. يمكن إعطاؤك لاكسيرا إذا كنت تخضعين لعملية قيصرية.</p><p dir="RTL">يجب تعليق الرضاعة الطبيعية لمدة 6 ساعات بعد استخدام هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">لا تقود السيارة أو تستخدم الآلات حتى ينصحك طبيبك بأنها آمنة. نظرا لأن لاكسيرا يعطى كجزء من مخدر عام، فقد تشعر بالتعب أو الضعف أو الدوار لبعض الوقت بعد ذلك. سيكون طبيب التخدير قادرا على تقديم المشورة لك بشأن المدة التي من المحتمل أن تستمر فيها الآثار.</p><p dir="RTL"><strong>لاكسيرا يحتوي على الصوديوم </strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملجم) لكل / أمبولة، أي تعتبر &quot;خالية من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة </strong></p><p dir="RTL">سيقوم طبيب التخدير الخاص بك بتحديد جرعة لاكسيرا التي تحتاجها بناء على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع المخدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المدة المتوقعة للعملية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تتناولها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالتك الصحية</p><p dir="RTL">الجرعة العادية هي 0.6 ملجم لكل كيلوجرام من وزن الجسم وسيستمر التأثير من 30 إلى 40 دقيقة.</p><p dir="RTL"><strong>كيف يتم إعطاء لاكسيرا </strong></p><p dir="RTL">سيتم إعطاؤك لاكسيرا من قبل طبيب التخدير الخاص بك. يتم إعطاء لاكسيرا عن طريق الوريد (في الوريد)، إما كحقن واحد أو كتسريب مستمر (بالتنقيط).</p><p dir="RTL">هذا الدواء مخصص للاستخدام لمرة واحدة فقط. يجب التخلص من أي محلول غير مستخدم للحقن / التسريب.</p><p dir="RTL"><strong>إذا تم إعطاؤك لاكسيرا أكثر من الموصى به </strong></p><p dir="RTL">نظرا لأن طبيب التخدير الخاص بك سيراقب حالتك بعناية، فمن غير المرجح أن يتم إعطاؤك الكثير من لاكسيرا. ومع ذلك، إذا حدث ذلك، فسوف يبقيك طبيب التخدير تتنفس بشكل مصطنع (على جهاز التنفس الصناعي) حتى تتمكن من التنفس بنفسك. سوف تبقى نائما أثناء حدوث ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، على الرغم من أن ليس كل المرضى يتعرضون لها. إذا حدثت هذه الآثار الجانبية أثناء وجودك تحت التخدير، سيتم رؤيتها وعلاجها من قبل طبيب التخدير.</p><p dir="RTL"><strong>غير شائع (قد يؤثر على ما يصل إلى 1 من كل 100 شخص) </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في معدل ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء فعال جدا أو غير فعال بما فيه الكفاية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء يعمل لفترة أطول من المتوقع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالقرب من موقع الحقن</p><p dir="RTL"><strong>نادر جدا (قد يؤثر على ما يصل إلى 1 من كل 10000 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية (فرط الحساسية) (مثل صعوبة التنفس وانهيار الدورة الدموية والصدمة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صفير الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو طفح جلدي أو بثور أو احمرار في الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما يلاحظ خلل العضلات على المدى الطويل مع لاكسيرا والأدوية المضادة للالتهابات (تستخدم الكورتيكوستيرويدات في وحدة العناية المركزة في نفس الوقت في المرضى المصابين بأمراض خطيرة (اعتلال عضلي الستيرويد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاعفات مجرى الهواء للتخدير</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج الأوعية الدموية التاجية التحسسي الشديد (متلازمة كونيس) مما يؤدي إلى ألم في الصدر (الذبحة الصدرية) أو نوبة قلبية (احتشاء عضلة القلب)</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التردد من البيانات المتاحة) </strong></p><p dir="RTL"><strong>إذا أصبح أي من هذه الآثار الجانبية خطيرا، </strong>أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، <strong>أخبر طبيب التخدير أو أي طبيب آخر. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدا عن متناول ونظر الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على ملصق الأمبولة والكرتون بعد انتهاء الصلاحية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يخزن في الثلاجة (2 درجة مئوية -8 درجات مئوية).</p><p dir="RTL">لا تجمد الأمبول.</p><p dir="RTL">احتفظ بالأمبولة في الكرتون الخارجي للحماية من الضوء.</p><p dir="RTL">يمكن أيضا حفظ لاكسيرا خارج الثلاجة عند درجة حرارة تصل إلى 25 درجة مئوية لمدة أقصاها 12 أسبوعا.</p><p dir="RTL">يجب استخدام المحلول مباشرة بعد فتح الأمبولة.</p><p dir="RTL"><strong>العمر الافتراضي قيد الاستخدام للمنتج الطبي المخفف </strong></p><p dir="RTL">بعد التخفيف باستخدام سوائل التسريب، تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام لمدة 24 ساعة عند 25 درجة مئوية.&nbsp; من وجهة نظر مكروبيولوجية، يجب استخدام المنتج المخفف على الفور. إذا لم يتم استخدامها على الفور، فإن أوقات وظروف التخزين أثناء الاستخدام قبل الاستخدام هي مسؤولية المستخدم / المسؤول ولن تكون عادة أطول من 24 ساعة عند 2 إلى 8 درجات مئوية، ما لم يحدث التخفيف في ظروف معقمة خاضعة للرقابة والتحقق من صحتها.</p><p>لا تستخدم هذا الدواء إذا لاحظت أن المحلول غير نقى وغير خال من الجسيمات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي: </strong>روكورونيوم بروميد.<strong> </strong></p><p dir="RTL">كل مل من محلول الحقن / التسريب يحتوي على 10 ملجم روكورونيوم بروميد.</p><p dir="RTL">كل أمبولة مع 5 مل تحتوي على 50 ملجم روكورونيوم بروميد.</p><p dir="RTL"><strong>المكونات الأخرى هي: </strong></p><p dir="RTL">كلوريد الصوديوم، اسيتات الصوديوم اللامائي، حمض الخليك الجليدي 30 ٪، هيدروكسيد الصوديوم BP، النيتروجين، الماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول الروكورونيوم 10 ملجم / مل للحقن / التسريب هو محلول نقى، عديم اللون الى بني مصفر شاحب، يحتوي على جزيئات مرئية حرة</p><p dir="RTL">أمبولات من 5 مل</p><p dir="RTL">أحجام العبوة:</p><p dir="RTL">10 &times; 5 مل أمبولات</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الدوائية</strong></p><p>مصنع الأدوية بالقصيم</p><p dir="RTL">المملكة العربية السعودية<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر 2023 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LAXIRA 10 mg/mL solution for injection/infusion
Rocuronium bromide 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of solution of Laxira contains 10 mg rocuronium bromide.
Each ampoule with 5 ml contains 50 mg rocuronium bromide.
Excipient with known effect
Sodium 1.6 - 3.7 mg per mL
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion
Clear, colorless up to pale brown-yellowish solution, free visible particles 
PH: 3.8-4.2

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rocuronium bromide is indicated in adult and pediatric patients (from term neonates to adolescents [0 to &lt;18 years]) as an adjunct to general anesthesia to facilitate tracheal intubation during routine induction and to provide skeletal muscle relaxation during surgery. In adults, Rocuronium bromide is also indicated to facilitate tracheal intubation during rapid sequence induction and as an adjunct in the intensive care unit (ICU) ( to facilitate intubation), for short term use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Like other neuromuscular blocking agents, Rocuronium bromide should only be administered by, or under supervision of, experienced clinicians who are familiar with the action and use of these medicinal products.</p><p>As with other neuromuscular blocking agents, the dosage of Rocuronium bromide should be individualized in each patient. The method of anesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other medicinal products that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose.</p><p>The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery.</p><p>Inhalational anaesthetics do potentiate the neuromuscular blocking effects of Rocuronium bromide. This potentiation however, becomes clinically relevant in the course of anaesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with Rocuronium bromide should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of Rocuronium bromide during long lasting procedures (longer than 1 hour) under inhalational anaesthesia (see section 4.5).</p><p>In adult patients the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to long lasting surgical procedures and for use in the intensive care unit.</p><p><strong>Surgical Procedures</strong></p><p><em>Tracheal intubation</em></p><p>The standard intubating dose during routine anaesthesia is 0.6 mg/kg rocuronium bromide, after which adequate intubation conditions are established within 60 seconds in nearly all patients. A dose of 1.0 mg/kg rocuronium bromide is recommended for facilitating tracheal intubation conditions during rapid sequence induction of anaesthesia, after which adequate intubation conditions are established within 60 seconds in nearly all patients. If a dose of 0.6 mg/kg rocuronium bromide is used for rapid sequence induction of anaesthesia, it is recommended to intubate the patient 90 seconds after administration of rocuronium bromide.</p><p>For use of rocuronium bromide during rapid sequence induction of anaesthesia in patients undergoing Caesarean section reference is made to section 4.6.</p><p><em>Higher doses</em></p><p>Should there be reason for selection of larger doses in individual patients, there is no indication from clinical studies that the use of initial doses up to 2 mg/kg rocuronium bromide is associated with an increased frequency or severity of cardiovascular effects. The use of these high dosages of rocuronium bromide decreases the onset time and increases the duration of action (see section 5.1).</p><p><em>Maintenance dosing</em></p><p>The recommended maintenance dose is 0.15 mg/kg rocuronium bromide; in the case of long-term inhalational anaesthesia this should be reduced to 0.075-0.1 mg/kg rocuronium bromide.</p><p>The maintenance doses should best be given when twitch height has recovered to 25% of control twitch height, or when 2 to 3 responses to train of four stimulation are present.</p><p><em>Continuous infusion</em></p><p>If rocuronium bromide is administered by continuous infusion, it is recommended to give a loading dose of 0.6 mg/kg rocuronium bromide and, when neuromuscular block starts to recover, to start administration by infusion. The infusion rate should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 to 2 responses to train of four stimulation.</p><p>In adults under intravenous anaesthesia, the infusion rate required to maintain neuromuscular block at this level ranges from 0.3-0.6 mg/kg/h (300-600 micrograms/kg/h) and under inhalational anaesthesia the infusion rate ranges from 0.3-0.4 mg/kg/h. Continuous monitoring of neuromuscular block is essential since infusion rate requirements vary from patient to patient and with the anaesthetic method used.</p><p><em>Paediatric population</em></p><p>For neonates (0-27 days), infants (28 days&ndash;2 months), toddlers (3-23 months), children (2-11 years) and adolescents (12&ndash;17 years) the recommended intubation dose during routine anaesthesia and maintenance dose are similar to those in adults. However, the duration of action of the single intubating dose will be longer in neonates and infants than in children (see section 5.1).</p><p>For continuous infusion in paediatrics, the infusion rates, with the exception of children (2-11 years), are the same as for adults. For children aged 2-11 years, higher infusion rates might be necessary. Thus, for children (2-11 years) the same initial infusion rates as for adults are recommended and then this should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 responses to train of four stimulation during the procedure.</p><p>The experience with rocuronium bromide in rapid sequence induction in paediatric patients is limited. Rocuronium bromide is therefore not recommended for facilitating tracheal intubation conditions during rapid sequence induction in paediatric patients.</p><p><em>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</em></p><p>The standard intubation dose for geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure during routine anaesthesia is 0.6 mg/kg rocuronium bromide. A dose of 0.6 mg/kg should be considered for rapid sequence induction of anaesthesia in patients in which a prolonged duration of action is expected. Regardless of the anaesthetic technique used, the recommended maintenance dose for these patients is 0.075-0.1 mg/kg rocuronium bromide, and the recommended infusion rate is 0.3-0.4 mg/kg/h (see Continuous infusion). (See also section 4.4.).</p><p><em>Overweight and obese patients</em></p><p>When used in overweight or obese patients (defined as patients with a body weight of 30% or more above ideal body weight) doses should be reduced taking into account ideal body weight.</p><p><strong>Intensive Care Procedures</strong></p><p><em>Tracheal intubation</em></p><p>For tracheal intubation, the same doses should be used as described above under surgical procedures.</p><p><em>Special populations</em></p><p>Rocuronium bromide is not recommended for the facilitation of mechanical ventilation in the intensive care due to a lack of data on safety and efficacy.</p><p><u>Method of administration</u></p><p>This medicinal product is for single use only. Any unused solution should be discarded.</p><p>Rocuronium bromide is administered intravenously either as a bolus injection or as a continuous infusion (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to rocuronium or to the bromide ion or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rocuronium bromide should be administered only by anaesthetists familiar with the use of neuromuscular blocking agents and when facilities for controlled ventilation, insufflation with oxygen and tracheal intubation are available for immediate use.</p><p><strong>Appropriate Administration and Monitoring</strong></p><p>Since Rocuronium bromide causes paralysis of the respiratory muscles, ventilatory support is mandatory for patients treated with this medicinal product until adequate spontaneous respiration is restored.</p><p>As with all neuromuscular blocking agents, it is important to anticipate intubation difficulties, particularly when used as part of a rapid sequence induction technique. In the case of intubation difficulties resulting in a clinical need for immediate reversal of rocuronium induced neuromuscular block, the use of a reversal agent should be considered.</p><p><strong>Residual Curarization</strong></p><p>As with other neuromuscular blocking agents, residual curarization has been reported for Rocuronium bromide. In order to prevent complications resulting from residual curarization, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular block. Geriatric patients (65 years or older) may be at increased risk for residual neuromuscular block. Other factors which could cause residual curarization after extubation in the post-operative phase (such as drug interactions or patient condition) should also be considered. If not used as part of standard clinical practice, the use of a reversal agent (such as sugammadex or acetylcholinesterase inhibitors) should be considered, especially in those cases where residual curarization is more likely to occur.</p><p><strong>Anaphylaxis</strong></p><p>Anaphylactic reactions can occur following the administration of neuromuscular blocking agents. Precautions for treating such reactions should always be taken. Particularly in the case of previous anaphylactic reactions to neuromuscular blocking agents, special precautions should be taken since allergic cross-reactivity to neuromuscular blocking agents has been reported.</p><p><strong>Use in an Intensive Care Unit</strong></p><p>In general, following long term use of neuromuscular blocking agents in the ICU, prolonged paralysis and/or skeletal muscle weakness has been noted. In order to help preclude possible prolongation of neuromuscular block and/or overdosage it is strongly recommended that neuromuscular transmission is monitored throughout the use of neuromuscular blocking agents. In addition, patients should receive adequate analgesia and sedation. Furthermore, neuromuscular blocking agents should be titrated to effect in the individual patients by or under supervision of experienced clinicians who are familiar with their actions and with appropriate neuromuscular monitoring techniques.</p><p>Myopathy after long term administration of other non-depolarizing neuromuscular blocking agents in the ICU in combination with corticosteroid therapy has been reported regularly. Therefore, for patients receiving both neuromuscular blocking agents and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible.</p><p><strong>Use with Suxamethonium</strong></p><p>If suxamethonium is used for intubation, the administration of Rocuronium bromide should be delayed until the patient has clinically recovered from the neuromuscular block induced by suxamethonium.</p><p>Because rocuronium bromide is always used with other drugs and because of the risk of malignant hyperthermia during anaesthesia, even in the absence of known triggering factors, physicians should be aware of the early symptoms, confirmatory diagnosis and treatment of malignant hyperthermia prior to the start of anaesthesia. Animal studies have shown that rocuronium bromide is not a triggering factor for malignant hyperthermia. Rare cases of malignant hyperthermia with rocuronium bromide have been observed through post-marketing surveillance however, the causal association has not been proven.</p><p><strong>The following conditions may influence the pharmacokinetics and/or pharmacodynamics of Rocuronium bromide:</strong></p><p><u>Hepatic and/or biliary tract disease and renal failure</u></p><p>Because rocuronium is excreted in urine and bile, it should be used with caution in patients with clinically significant hepatic and/or biliary diseases and/or renal failure. In these patient groups prolongation of action has been observed with doses of 0.6 mg/kg rocuronium bromide.</p><p><u>Prolonged circulation time</u></p><p>Conditions associated with prolonged circulation time such as cardiovascular disease, old age and oedematous state resulting in an increased volume of distribution, may contribute to a slower onset of action. The duration of action may also be prolonged due to a reduced plasma clearance.</p><p><u>Neuromuscular disease</u></p><p>Like other neuromuscular blocking agents, Rocuronium bromide should be used with extreme caution in patients with a neuromuscular disease or after poliomyelitis since the response to neuromuscular blocking agents may be considerably altered in these cases. The magnitude and direction of this alteration may vary widely. In patients with myasthenia gravis or with the myasthenic (Eaton-Lambert) syndrome, small doses of Rocuronium bromide may have profound effects and Rocuronium bromide should be titrated to the response.</p><p><u>Hypothermia</u></p><p>In surgery under hypothermic conditions, the neuromuscular blocking effect of Rocuronium bromide is increased and the duration prolonged.</p><p><u>Obesity</u></p><p>Like other neuromuscular blocking agents, Rocuronium bromide may exhibit a prolonged duration and a prolonged spontaneous recovery in obese patients when the administered doses are calculated on actual body weight.</p><p><u>Burns</u></p><p>Patients with burns are known to develop resistance to non-depolarising neuromuscular blocking agents. It is recommended that the dose is titrated to response.</p><p><u>Conditions which may increase the effects of Rocuronium bromide</u></p><p>Hypokalaemia (e.g. after severe vomiting, diarrhoea and diuretic therapy), hypermagnesemia, hypocalcaemia (after massive transfusions), hypoproteinaemia, dehydration, acidosis, hypercapnia, cachexia.</p><p>Severe electrolyte disturbances altered blood pH or dehydration should therefore be corrected when possible.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per /ampoule, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following medicinal products have been shown to influence the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents.</p><p><strong>Effect of other drugs on Rocuronium bromide</strong></p><p><u>Increased effect:</u></p><p>- Halogenated volatile anaesthetics: potentiate the neuromuscular block of rocuronium bromide. The effect only becomes apparent with maintenance dosing (see section 4.2). Reversal of the block with acetylcholinesterase inhibitors could also be inhibited.</p><p>- After intubation with suxamethonium (see section 4.4).</p><p>- Long-term concomitant use of corticosteroids and Rocuronium bromide in the ICU may result in prolonged duration of neuromuscular block or myopathy (see sections 4.4 and 4.8).</p><p><u>Other drugs:</u></p><p>- Antibiotics: aminoglycoside, lincosamide and polypeptide antibiotics, acylamino-penicillin antibiotics.</p><p>- Diuretics, quinidine and its isomer quinine, magnesium salts, calcium channel blocking agents, lithium salts, local anaesthetics (lidocaine i.v., bupivacaine epidural) and acute administration of phenytoin or &beta;-blocking agents.</p><p>Recurarization has been reported after post-operative administration of: aminoglycoside, lincosamide, polypeptide and acylamino-penicillin antibiotics, quinidine, quinine and magnesium salts (see section 4.4).</p><p><u>Decreased effect:</u></p><p>- Neostigmine, edrophonium, pyridostigmine</p><p>- Prior chronic administration of phenytoin or carbamazepine</p><p>- Calcium chloride and potassium chloride</p><p>- Protease inhibitors (gabexate, ulinastatin)</p><p><u>Variable effect:</u></p><p>- Administration of other non-depolarising neuromuscular blocking agents in combination with Rocuronium bromide may produce attenuation or potentiation of the neuromuscular block, depending on the order of administration and the neuromuscular blocking agent used.</p><p>- Suxamethonium given after the administration of Rocuronium bromide may produce potentiation or attenuation of the neuromuscular blocking effect of Rocuronium bromide.</p><p><strong><u>Effect of Rocuronium bromide on other drugs</u></strong></p><p>Rocuronium bromide combined with lidocaine may result in a quicker onset of action of lidocaine.</p><p><u>Paediatric population</u></p><p>No formal interaction studies have been performed. The above mentioned interactions for adults and their special warnings and precautions for use (see section 4.4) should also be taken into account for paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For rocuronium bromide, no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing rocuronium bromide to pregnant women.</p><p><u>Caesarean section</u></p><p>In patients undergoing Caesarean section, rocuronium bromide can be used as part of a rapid sequence induction technique, provided no intubation difficulties are anticipated and a sufficient dose of anaesthetic agent is administered or following suxamethonium facilitated intubation. Rocuronium bromide, administered in doses of 0.6 mg/kg has been shown to be safe in patients undergoing Caesarean section. Rocuronium bromide does not affect Apgar score, foetal muscle tone or cardiorespiratory adaptation. From umbilical cord blood sampling it is apparent that only limited placental transfer of rocuronium bromide occurs, which does not lead to the observation of clinical adverse effects in the newborn.</p><p><em>Note 1:</em>&nbsp;doses of 1.0 mg/kg have been investigated during rapid sequence induction of anaesthesia, but not in Caesarean section patients. Therefore, only a dose of 0.6 mg/kg is recommended in this patient group.</p><p><em>Note 2:</em>&nbsp;reversal of neuromuscular block induced by neuromuscular blocking agents may be inhibited or unsatisfactory in patients receiving magnesium salts for toxemia of pregnancy because magnesium salts enhance neuromuscular blockade. Therefore, in these patients the dosage of rocuronium bromide should be reduced and be titrated to twitch response.</p><p><u>Breastfeeding</u></p><p>It is unknown whether rocuronium bromide is excreted in human breast milk. Animal studies have shown insignificant levels of rocuronium bromide in breast milk.</p><p>Rocuronium bromide should be given to lactating women only when the attending physician decides that the benefits outweigh the risks. After the administration of a single dose, it is recommended to abstain from next breastfeeding for five elimination half-lives of rocuronium, i.e. for about 6 hours.</p><p><u>Fertility</u></p><p>There is no data available regarding the effect in the fertility for this product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since rocuronium bromide is used as an adjunct to general anaesthesia, the usual precautionary measures after a general anaesthesia should be taken for ambulatory patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly occurring adverse drug reactions include injection site pain/reaction, changes in vital signs and prolonged neuromuscular block. The most frequently reported serious adverse drug reactions during post-marketing surveillance is &#39;anaphylactic and anaphylactoid reactions&#39; and associated symptoms. See also the explanations below the table.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA SOC</p></td><td style="vertical-align:top"><p>Preferred term<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon/rare<sup>2</sup></p><p>(&lt;1/100, &gt;1/10 000)</p></td><td style="vertical-align:top"><p>Very rare</p><p>(&lt;1/10 000)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity</p><p>Anaphylactic reaction</p><p>Anaphylactoid reaction</p><p>Anaphylactic shock</p><p>Anaphylactoid shock</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flaccid paralysis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Kounis syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Circulatory collapse and shock</p><p>Flushing</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Angioneurotic oedema</p><p>Urticaria</p><p>Rash</p><p>Erythematous rash</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscular weakness<sup>3</sup></p><p>Steroid myopathy<sup>3</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Drug ineffective</p><p>Drug effect/ therapeutic response decreased</p><p>Drug effect/ therapeutic response increased</p><p>Injection site pain</p><p>Injection site reaction</p></td><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Prolonged neuromuscular block</p><p>Delayed recovery from anaesthesia</p></td><td style="vertical-align:top"><p>Airway complication of anaesthesia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p>MedDRA version 8.1</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Frequencies are estimates derived from post-marketing surveillance reports and data from the general literature.</p><p><sup>2</sup>&nbsp;Post-marketing surveillance data cannot give precise incidence figures. For that reason, the reporting frequency was divided over three rather than five categories.</p><p><sup>3</sup>&nbsp;After long-term use in the ICU.</p><p><u>Anaphylaxis</u></p><p>Although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including Rocuronium bromide, have been reported. Anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). These reactions have, in some cases, been fatal. Due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.</p><p>Since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematous reaction at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these drugs.</p><p>In clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3-0.9 mg/kg rocuronium bromide.</p><p><u>Prolonged neuromuscular block</u></p><p>The most frequent adverse reaction to nondepolarising blocking agents as a class consists of an extension of the drug&#39;s pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.</p><p><u>Myopathy</u></p><p>Myopathy has been reported after the use of various neuromuscular blocking agents in the ICU in combination with corticosteroids (see section 4.4).</p><p><u>Local injection site reactions</u></p><p>During rapid sequence induction of anaesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. In clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anaesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anaesthesia with fentanyl and thiopental.</p><p><u>Paediatric population</u></p><p>A meta-analysis of 11 clinical studies in paediatric patients (n=704) with rocuronium bromide (up to 1 mg/kg) showed that tachycardia was identified as adverse drug reaction with a frequency of 1.4%.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>PV address</p></td></tr><tr><td style="vertical-align:top"><p>English</p></td><td style="vertical-align:top"><p>Arabic</p></td></tr><tr><td style="vertical-align:top"><p>For Saudi Arabia:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصال هيئة الغذاء والدواء :19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني npc.drug@sfda.gov.sa :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p></td></tr><tr><td style="vertical-align:top"><p>For UAE</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacovigilance &amp; Medical Device section&nbsp;<br />P.O.Box: 1853 &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: 80011111&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>pv@moh.gov.ae</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Department&nbsp;<br />Ministry of Health &amp; Prevention&nbsp;<br />Dubai</p><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الإمارات العربية المتحدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قسم اليقظة الدوائية والأجهزة الطبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صندوق البريد: 1853</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 80011111</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: pv@moh.gov.ae</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قسم الأدوية، وزارة الصحة والوقاية، دبي.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>For Oman</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Department of Pharmacovigilance &amp; Drug Information</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ministry of Health, Sultanate of&nbsp;Oman</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phone Nos. 22357687 / 22357686</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: 22358489</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: dg-padc@moh.gov.om</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:&nbsp;<u>www.moh.gov.om</u></p><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">سلطنة عُمان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دائرة التيقظ والمعلومات الدوائية&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المديرية العامة للصيدلة والرقابة الدوائية&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزارة الصحة، سلطنة عمان&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف:&nbsp;0096822357686/0096822357687</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس:00968522358489</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني:&nbsp;<u>dg-padc@moh.gov.om</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع&nbsp;الالكتروني:&nbsp;<u>www.moh.gov.om</u></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>For Jordan</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; JFDA&rsquo;s site: Jfda.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; JFDA PV email: jpc@jfda.jo</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; JFDA reporting link: https://primaryreporting.who.umc.org/JO</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phone: +962-6-5632000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QR code</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_s1026" type="#_x0000_t75"
   alt="Image preview" style='position:absolute;margin-left:0;margin-top:7.3pt;
   width:53.5pt;height:53.5pt;z-index:251659264;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
   mso-height-relative:page'>
   <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title="Image preview"/>
   <w:wrap type="square"/>
  </v:shape><![endif]--><img width="71" height="71" alt="" vspace="0" hspace="0" border="0" style="width:71px;height:71px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الأردن:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المؤسسة العامة للغذاء والدواء الأردنية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع&nbsp;الالكتروني:&nbsp;Jfda.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني:&nbsp;jpc@jfda.jo</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف:&nbsp; +962-6-5632000</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رابد الابلاغ : https://primaryreporting.who.umc.org/JO</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رمز الإستجابة السريع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
   id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75" alt="Image preview"
   style='width:54pt;height:54pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title="Image preview"/>
  </v:shape><![endif]--><img width="72" height="72" alt="Image preview" src="data:image/jpeg;base64,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" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdosage and prolonged neuromuscular block, the patient should continue to receive ventilatory support and sedation. There are two options for the reversal of neuromuscular block: (1) In adults, sugammadex can be used for reversal of intense (profound) and deep block. The dose of sugammadex to be administered depends on the level of neuromuscular block. (2) An acetylcholinesterase inhibitor (e.g. neostigmine, edrophonium, pyridostigmine) or sugammadex can be used once spontaneous recovery starts and should be administered in adequate doses. When administration of an acetylcholinesterase inhibiting agent fails to reverse the neuromuscular effects of Rocuronium bromide, ventilation must be continued until spontaneous breathing is restored. Repeated dosage of an acetylcholinesterase inhibitor can be dangerous.</p><p>In animal studies, severe depression of cardiovascular function, ultimately leading to cardiac collapse did not occur until a cumulative dose of 750 x ED90 (135 mg/kg rocuronium bromide) was administered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group:</u>&nbsp;Muscle relaxants, peripherally acting agents, other quaternary ammonium compounds ATC code: M03AC09</p><p><u>Mechanism of action</u></p><p>Rocuronium bromide is a fast onset, intermediate acting non-depolarising neuromuscular blocking agent, possessing all of the characteristic pharmacological actions of this class of medicinal products (curariform). It acts by competing for nicotinic cholinoceptors at the motor end-plate. This action is antagonised by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine.</p><p><u>Pharmacodynamic effects</u></p><p>The ED90 (dose required to produce 90% depression of the twitch response of the thumb to stimulation of the ulnar nerve) during intravenous anaesthesia is approximately 0.3 mg/kg rocuronium bromide. The ED95 in infants is lower than in adults and children (0.25, 0.35 and 0.40 mg/kg respectively).</p><p>The clinical duration (the duration until spontaneous recovery to 25% of control twitch height) with 0.6 mg/kg rocuronium bromide is 30&ndash;40 minutes. The total duration (time until spontaneous recovery to 90% of control twitch height) is 50 minutes. The mean time of spontaneous recovery of twitch response from 25 to 75% (recovery index) after a bolus dose of 0.6 mg/kg rocuronium bromide is 14 minutes.</p><p>With lower dosages of 0.3-0.45 mg/kg rocuronium bromide (1 -1&frac12; x ED90), onset of action is slower and duration of action is shorter. With high doses of 2 mg/kg, clinical duration is 110 minutes.</p><p><u>Intubation during routine anaesthesia</u></p><p>Within 60 seconds following intravenous administration of a dose of 0.6 mg/kg rocuronium bromide (2 x ED90 under intravenous anaesthesia), adequate intubation conditions can be achieved in nearly all patients of which in 80% intubation conditions are rated excellent. General muscle paralysis adequate for any type of procedure is established within 2 minutes. After administration of 0.45 mg/kg rocuronium bromide, acceptable intubation conditions are present after 90 seconds.</p><p><u>Rapid Sequence Induction</u></p><p>During rapid sequence induction of anaesthesia under propofol or fentanyl/thiopental anaesthesia, adequate intubation conditions are achieved within 60 seconds in 93% and 96% of the patients respectively, following a dose of 1.0 mg/kg rocuronium bromide. Of these, 70% are rated excellent. The clinical duration with this dose approaches 1 hour, at which time the neuromuscular block can be safely reversed. Following a dose of 0.6 mg/kg rocuronium bromide, adequate intubation conditions are achieved within 60 seconds in 81% and 75% of the patients during a rapid sequence induction technique with propofol or fentanyl/thiopental, respectively.</p><p><u>Paediatric population</u></p><p>Mean onset time in infants, toddlers and children at an intubation dose of 0.6 mg/kg is slightly shorter than in adults. Comparison within paediatric age groups showed that the mean onset time in neonates and adolescents (1.0 min) is slightly longer than in infants, toddlers and children (0.4, 0.6 and 0.8 min., respectively). The duration of relaxation and the time to recovery tend to be shorter in children compared to infants and adults. Comparing within paediatric age groups demonstrated that mean time to reappearance of T<sub>3</sub>&nbsp;was prolonged in neonates and infants (56.7 and 60.7 min., respectively) when compared to toddlers, children and adolescents (45.4, 37.6 and 42.9 min., respectively).</p><p><strong>Mean (SD) time to onset and clinical duration following 0.6 mg/kg rocuronium initial intubating dose* during sevoflurane/nitrous oxide and isoflurane/nitrous oxide (maintenance) anaesthesia (Paediatric patients) PP group.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Time to maximum block** (min)</p></td><td style="vertical-align:top"><p>Time to reappearance of T<sub>3</sub>** (min)</p></td></tr><tr><td style="vertical-align:top"><p>Neonates (0 - 27 days) n = 10</p></td><td style="vertical-align:top"><p>0.98 (0.62)</p></td><td style="vertical-align:top"><p>56.69 (37.04) n=9</p></td></tr><tr><td style="vertical-align:top"><p>Infants (28 days - 2 months) n=11</p></td><td style="vertical-align:top"><p>0.44 (0.19) n=10</p></td><td style="vertical-align:top"><p>60.71 (16.52)</p></td></tr><tr><td style="vertical-align:top"><p>Toddler (3 months&ndash;23 months) n=28</p></td><td style="vertical-align:top"><p>0.59 (0.27)</p></td><td style="vertical-align:top"><p>45.46 (12.94) n=27</p></td></tr><tr><td style="vertical-align:top"><p>Children (2-11 years) n = 34</p></td><td style="vertical-align:top"><p>0.84 (0.29)</p></td><td style="vertical-align:top"><p>37.58 (11.82)</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents (12-17 years) n = 31</p></td><td style="vertical-align:top"><p>0.98 (0.38)</p></td><td style="vertical-align:top"><p>42.90 (15.83) n = 30</p></td></tr></tbody></table><p>* Dose of rocuronium administered within 5 seconds</p><p>** Calculated from the end of administration of the rocuronium intubating dose</p><p><u>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</u></p><p>The duration of action of maintenance doses of 0.15 mg/kg rocuronium bromide might be somewhat longer under enflurane and isoflurane anaesthesia in geriatric patients and in patients with hepatic and/or renal disease (approximately 20 minutes) than in patients without impairment of excretory organ functions under intravenous anaesthesia (approximately 13 minutes) (see section 4.2). No accumulation of effect (progressive increase in duration of action) with repetitive maintenance dosing at the recommended level has been observed.</p><p><u>Intensive Care Unit</u></p><p>Following continuous infusion in the Intensive Care Unit, the time to recover of the train of four ratio to 0.7 is not significantly correlated to the total duration of rocuronium infusion. After a continuous infusion for 20 hours or more the median (range) time between return of T<sub>2</sub>&nbsp;to train of four stimulation and recovery of the train of four ratio to 0.7 varied between 0,8 and 12,5 hours in patients without multiple organ failure and 1.2 &ndash; 25.5 hours in patients with multiple organ failure.</p><p><u>Cardiovascular surgery</u></p><p>In patients scheduled for cardiovascular surgery the most common cardiovascular changes during the onset of maximum block following 0.6-0.9 mg/kg rocuronium bromide are a slight and clinically insignificant increase in heart rate up to 9% and an increase in mean arterial blood pressure up to 16% from the control values.</p><p><u>Reversal of muscle relaxation</u></p><p>The action of rocuronium can be antagonised either by Sugammadex or by acetylcholinesterase inhibitors, (neostigmine, pyridostigmine or edrophonium). Sugammadex can be given for routine reversal (at 1-2 post-tetanic counts to reappearance of T<sub>2</sub>) or immediate reversal. Acetylcholinesterase inhibitors can be administered at reappearance of T<sub>2</sub>&nbsp;or at the first signs of clinical recovery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After intravenous administration of a single bolus dose of rocuronium bromide the plasma concentration time course runs in three exponential phases. In normal adults, the mean (95%CI) elimination half-life is 73 (66-80) minutes, the (apparent) volume of distribution at steady state conditions is 203 (193-214) mL/kg and plasma clearance is 3.7 (3.5-3.9) mL/kg/min.</p><p>In controlled studies the plasma clearance in geriatric patients and in patients with renal dysfunction was reduced, in most studies however without reaching the level of statistical significance. In patients with hepatic disease, the mean elimination half-life is prolonged by 30 minutes and the mean plasma clearance is reduced by 1 mL/kg/min. (see section 4.2).</p><p><u>Paediatric population</u></p><p>Pharmacokinetics of rocuronium bromide in paediatric patients (n=146) with ages ranging from 0 to 17 years were evaluated using a population analysis of the pooled pharmacokinetic datasets from two clinical trials under sevoflurane (induction) and isoflurane/nitrous oxide (maintenance) anaesthesia. All pharmacokinetic parameters were found to be linearly proportional to body weight illustrated by a similar clearance (1 hr<sup>-1</sup>kg<sup>-1</sup>). The volume of distribution (l kg<sup>-1</sup>) and elimination half-life (h) decrease with age (years). The pharmacokinetic parameters of typical paediatrics within each age group are summarized below:</p><p><strong>Estimated PK parameters (Mean [SD]) of rocuronium bromide in typical paediatric patients during sevoflurane and nitrous oxide (induction) and isoflurane/nitrous oxide (maintenance anaesthesia)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2"><p>Pk Parameters</p></td><td colspan="5"><p>Patient age range</p></td></tr><tr><td><p>Term Newborn infants</p><p>(0-27 days)</p></td><td><p>Infants</p><p>(28 days to 2 months)</p></td><td><p>Toddlers</p><p>(3-23 months)</p></td><td><p>Children</p><p>(2-11 years)</p></td><td><p>Adolescents (12-17 years)</p></td></tr><tr><td><p>CL L/kg/hr</p></td><td><p>0.31 (0.07)</p></td><td><p>0.30 (0.08)</p></td><td><p>0.33 (0.10)</p></td><td><p>0.35 (0.09)</p></td><td><p>0.29 (0.14)</p></td></tr><tr><td><p>Volume of distribution</p><p>(L/kg)</p></td><td><p>0.42 (0.06)</p></td><td><p>0.31 (0.03)</p></td><td><p>0.23 (0.03)</p></td><td><p>0.18 (0.02)</p></td><td><p>0.18 (0.01)</p></td></tr><tr><td><p>t<sub>&frac12;</sub>&nbsp;&beta; (hr)</p></td><td><p>1.1 (0.2)</p></td><td><p>0.9 (0.3)</p></td><td><p>0.8 (0.2)</p></td><td><p>0.7 (0.2)</p></td><td><p>0.8 (0.3)</p></td></tr></tbody></table><p><u>Intensive Care unit</u></p><p>When administered as a continuous infusion to facilitate mechanical ventilation for 20 hours or more, the mean elimination half-life and the mean (apparent) volume of distribution at steady state are increased.</p><p>A large between patient variability is found in controlled clinical studies, related to nature and extent of (multiple) organ failure and individual patient characteristics. In patients with multiple organ failure a mean (&plusmn; SD) elimination half-life of 21.5 (&plusmn; 3.3) hours, a (apparent) volume of distribution at steady state of 1.5 (&plusmn; 0.8) L/kg and a plasma clearance of 2.1 (&plusmn; 0.8) mL/kg/min were found. (see section 4.2).</p><p>Rocuronium bromide is excreted in urine and bile. Excretion in urine approaches 40% within 12-24 hours.</p><p>After injection of a radiolabeled dose of rocuronium bromide, excretion of the radiolabel is on average 47% in urine and 43% in faeces after 9 days. Approximately 50% is recovered as the parent compound. No metabolites are detected in plasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In subacute toxicity studies rocuronium bromide was intravenously administered to cats and dogs up to a dose of 37 x ED90 and 60 x ED90 respectively two times per week for a period of 4 weeks. Unforeseen mortalities occurred in three out of seven dogs at the dose of 60 x ED90 (10,8 mg per kg body weight). The cause of death could not be established, but was considered to be related to interactions between rocuronium treatment and experimental procedures and/or instrumentation and anaesthesia.</p><p>No chronic toxicity studies of rocuronium bromide have been conducted.</p><p><em>In vivo</em>&nbsp;and&nbsp;<em>in vitro</em>&nbsp;mutagenicity studies have revealed no mutagenic potential of rocuronium bromide.</p><p>No carcinogenicity studies of rocuronium bromide have been conducted.</p><p>Studies using sub-pharmacological intravenous doses of rocuronium bromide in rats during organogenesis have produced no evidence of embryolethal effects, teratological alterations or foetal growth inhibition. Rocuronium bromide crosses the placental barrier in rats to a limited extent, and is recovered in milk in small amounts.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:321px"><tbody><tr><td><p><strong>Name of Ingredients</strong></p><p><strong>(Active &amp; Inactive)</strong></p></td><td><p><strong>mg/5ml</strong></p><p><strong>Unit Dose</strong></p><p><strong>(mg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Rocuronium Bromide</p></td><td><p>50</p></td></tr><tr><td style="vertical-align:bottom"><p>Sodium Chloride</p></td><td><p>16.500</p></td></tr><tr><td style="vertical-align:bottom"><p>Sodium Acetate Anhydrous</p></td><td><p>10.00</p></td></tr><tr><td style="vertical-align:bottom"><p>Glacial Acetic Acid 30%</p></td><td><p>q.s. to pH 3.8 to 4.2</p></td></tr><tr><td style="vertical-align:bottom"><p>Sodium Hydroxide BP</p></td><td><p>q.s. to pH 3.8 to 4.2</p></td></tr><tr><td style="vertical-align:top"><p>Nitrogen</p></td><td style="vertical-align:top"><p>q.s.</p></td></tr><tr><td style="vertical-align:top"><p>Water for Injection</p></td><td style="vertical-align:top"><p>q.s. to 5ml</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Physical incompatibility has been documented for Rocuronium bromide when added to solutions containing the following active substances: amphotericin, amoxicillin, azathioprine, cefazolin, cloxacillin, dexamethasone, diazepam, enoximone, erythromycin, famotidine, furosemide, hydrocortisone sodium succinate, insulin, intralipid, methohexital, methylprednisolone, prednisolone sodium succinate, thiopental, trimethoprim and vancomycin.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>If Rocuronium bromide is administered via the same infusion line that is also used for other medicinal products, it is important that this infusion line is adequately flushed (e.g. with 0.9% NaCl) between administration of Rocuronium bromide and medicinal products for which incompatibility with Rocuronium bromide has been demonstrated or for which compatibility with Rocuronium bromide has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
Shelf-life after first opening.
The solution should be used immediately after opening the ampoule. Discard any unused content.
In-use shelf-life of diluted medicinal product
After dilution with infusion fluids (see section 6.6), chemical and physical in-use stability has been demonstrated for 24 hours at room temperature.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Store in Refrigerator</strong></p><p>Laxira should be stored at 2-8&deg;C in the dark and used within the expiry date given on the pack.</p><p><strong>Store out of the refrigerator</strong></p><p>Laxira should be stored outside the refrigerator at a temperature of up to 30&deg;C for maximum of 3 months based on the accelerated condition (30&deg;C/65RH) stability data. The product may be placed in and out the refrigerator at any points during 24-month shelf-life, but the total storage time outside the refrigerator must not exceed 3 months. The storage period does not exceed the labelled shelf-life.</p><p>Do not freeze.</p><p>Keep the ampoule in the outer carton to protect it from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear, colorless up to pale brown-yellowish solution, free visible particles</p><p>For ampoules: 5ml clear glass- ampule USP Type I</p><p><u>Pack sizes:</u></p><p>10 x 5 ml</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Laxira compatibility study performed in nominal concentrations of 0.5mg/ml and 2.0mg/ml up to 24 hours at room temperature. Laxira after dilution with infusion fluids has been shown to be compatible with: sodium chloride 9 mg/ml (0.9%) solution, glucose 50 mg/ml (5%) solution, glucose 33 mg/ml (3.3 %) in sodium chloride 3 mg/ml (0.3%) solution, water for injections and Ringer&rsquo;s Lactate solution.</p><p>&nbsp;</p><p>Administration should begin immediately after mixing and should be completed within 24 hours.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Do not use Rocuronium bromide if you notice that the solution is not clear and not free from particles.</p><p>Since Laxira does not contain a preservative, the solution should be used immediately after opening the Ampoules. If not used Immediately, in-use storage normally no be longer than 24 hours at 2-8&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by SPIMACO
AlQassim pharmaceutical plant
Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>